<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        24-249-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALFOSIN XR 10 mg prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALFUZOSIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Extended-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        70.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G04CA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What the medication is used for:</strong><br />Your doctor has prescribed ALFOSIN&reg;XR because you have a medical condition called benign prostatic hyperplasia (BPH) or acute urinary retention (AUR) related to BPH. This occurs in men.</p><p>&nbsp;</p><p><strong>What it does:</strong><br />ALFOSIN&reg;XR relaxes muscles in the prostate, bladder neck and base. This results in improved urine flow, and reduced BPH symptoms.</p><p>When taken during catheterization for sudden acute urinary retention, ALFOSIN&reg;XR may help you pass urine after catheter removal. Urinary catheters are flexible tubes placed in the bladder to drain urine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ALFOSIN&reg;XR is not indicated as a treatment to lower blood pressure.</p><p>ALFOSIN&reg;XR is not indicated nor recommended for use in women and children.</p><p>Prostate cancer and BPH cause many of the same symptoms. Prior to starting ALFOSIN&reg;XR, your doctor will examine you to rule out the presence of prostate cancer.</p><p>You (in particular, if you are receiving drugs to lower blood pressure) may experience low blood pressure and feel dizzy at the start of treatment, especially when getting up from a lying or sitting position. In such cases, lie down until the symptoms have completely disappeared.</p><p>&nbsp;</p><p><strong>Do not use ALFOSIN&reg;XR:</strong><br />If you have ever had an allergic reaction to Alfuzosin hydrochloride or to any ingredient in ALFOSIN&reg;XR (see below &ldquo;What the important nonmedicinal ingredients are :&rdquo;).</p><p>If you have a moderate to severe decrease in liver function.</p><p>If you take other alpha-blockers for high blood pressure or prostate problems.<br />If you take ketoconazole, ritonavir or itraconazole.</p><p>&nbsp;</p><p><strong>Take special care with ALFOSIN&reg;XR:</strong><br />Tell your doctor or pharmacist, before using the medication, if:</p><ul><li>You suffer liver or kidneys problems</li><li>You suffer from heart problems</li><li>You have ever had a reaction to the ingredients of this medication</li><li>You have had low blood pressure or signs of low blood pressure [fainting, dizziness] after taking another medicine</li><li>You or any family members have a condition known &nbsp; as &nbsp; congenital prolongation &nbsp; of &nbsp; the QT interval</li><li>You &nbsp; have &nbsp; suffered &nbsp; from QT prolongation following the administration of any drug</li><li>You have a family history of sudden death at an age &lt;50 years</li><li>You have suffered from electrolytes disturbances</li></ul><p>If you will have eye surgery, you must inform your eye surgeon that you are currently using ALFOSIN&reg;XR.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements:</strong><br />ALFOSIN&reg;XR is metabolized by specific enzymes in the liver. It is not known how combined use of any drugs, herbal products metabolized by the same enzymes or grapefruit juice may influence the efficacy or unwanted side effects of these drugs or herbal medicines.</p><p>Before using any prescription, over-the-counter medicines or herbal products, check with your doctor or your pharmacist.</p><p><u>Drugs that interact with ALFOSIN&reg;XR include:</u></p><ul><li>Alpha-blockers for high blood &nbsp;pressure or prostate problems</li><li>Anti-infection drugs: ketoconazole, itraconazole and ritonavir</li><li>Drugs for high blood pressure</li><li>Drugs for heart problems (nitrates)</li><li>Sildenafil</li></ul><p>&nbsp;</p><p><strong>Taking Alfosin&reg;XR with food and drink:</strong><br />Alfosin&reg;XR should be taken after a meal.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding:</strong><br />Alfosin&reg;XR is not prescribed or recommended for use in women.</p><p>&nbsp;</p><p><strong>Driving and using machines:</strong><br />You may feel dizzy and weak while taking Alfosin&reg;XR. If this happens do not drive or operate any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Usual dose:</strong><br />Follow your doctor&rsquo;s instructions very carefully about how to take ALFOSIN&reg;XR.</p><p>The recommended dosage is one tablet (10 mg) daily to be taken right after the same meal each day or from the first day of catheterization. &nbsp;The tablet should be swallowed whole.<br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>DO NOT CHEW, CRUSH, POUND, GRIND OR CRUNCH THE TABLET AS HIGH BLOOD LEVELS OF ALFOSIN&reg;XR MAY OCCUR.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>If you interrupt your treatment for several days or more, resume treatment after consulting with your doctor.</p><p>&nbsp;</p><p><strong>Overdose:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>In the event of overdosage, contact your doctor, hospital emergency department or regional Poison Control Centre</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>If you have taken too much ALFOSIN&reg;XR, immediately see your doctor or go to your nearest hospital emergency department. &nbsp;Show the doctor your bottle of tablets. Do this even if there are no signs &nbsp; of &nbsp; discomfort or poisoning. Overdose of ALFOSIN&reg;XR may lead to low blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all prescription drugs, ALFOSIN&reg;XR may cause side effects. Most side effects are mild. Side effects due to ALFOSIN&reg;XR may include dizziness and headache. In some cases, side effects may decrease or disappear while the patient continues to take ALFOSIN&reg;XR.</p><p>You may experience dizziness or fainting caused by a decrease in blood pressure after taking ALFOSIN&reg;XR. &nbsp; However, these effects are usually transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. &nbsp;In such cases, lie down until the symptoms have completely disappeared. &nbsp; Although these symptoms are unlikely, do not drive, operate machinery or perform hazardous tasks for 12 hours after the initial dose.</p><p>Cases of liver disorder have been observed in patients taking Alfuzosin hydrochloride. &nbsp;You should inform your doctor if you experience symptoms such as nausea, fatigue, jaundice (yellow color to the skin and/or eyes), dark urine, light-coloured stools, generalized itching or abdominal pain.<br />&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</p></td></tr><tr><td rowspan="2" colspan="2"><p><strong>Symptom/Effect</strong></p></td><td style="vertical-align:top" colspan="2"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td style="vertical-align:top" rowspan="2"><p><strong>Stop taking drug and call your doctor or pharmacist</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Only if severe</strong></p></td><td style="vertical-align:top"><p><strong>In all cases</strong></p></td></tr><tr><td rowspan="2"><p><strong>Common</strong></p></td><td><p>Headache</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Dizziness</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p><strong>Uncommon</strong></p></td><td><p>Fainting</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Liver disease</p></td><td><p>&nbsp;</p></td><td><p>✔</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>This is not a complete list of side effects. For any unexpected effects while taking ALFOSIN&reg;XR, contact your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ALFOSIN&reg;XR tablets should be stored at room temperature below 30&deg;C.</p><p>Keep ALFOSIN&reg;XR out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What the medicinal ingredient is:</strong><br />Alfuzosin&nbsp;</p><p>&nbsp;</p><p><strong>What the important nonmedicinal ingredients are:</strong><br />Hydroxypropyl methylcellulose, polyvinyl acetate phthalate, dibasic calcium phosphate dihydrate magnesium stearate, and yellow ferric oxide.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Prolonged-release tablets. Each tablet contains 10 mg Alfuzosin hydrochloride.
Tablets are yellow, round, flat-faced, beveled-edge tablets. Engraved “APO” on one side, “ALF” over “10” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised on 05/2015.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>دواعي استخدام هذا الدواء:</strong><br />لقد وصف لك الطبيب الدواء الفوسين&reg;XR لأنك تعاني من حالة مرضية تسُمى تضخم البروستاتا الحميد (BPH) أو احتباس البول الحاد (AUR)، المرتبط بتضخم البروستاتا الحميد. وتصيب هذه الحالة الرجال.</p><p>&nbsp;</p><p><strong>كيفية عمل الدواء:</strong><br />يعمل الفوسين&reg;XR على استرخاء عضلات البروستاتا وعنق وقاع المثانة. وينتج عن هذا تحسن تدفق البول وانخفاض أعراض تضخم البروستاتا الحميد. قد يساعد تناول الفوسين&reg;XR - أثناء تركيب قسطرة في حالة احتباس البول الحاد المفاجئ - على إخراج البول بعد إزالة القسطرة. ويقُصد بالقسطرة البولية تلك الأنابيب المرنة التي توضع داخل المثانة لتصريف البول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يوُصف الفوسين&reg;XR كعلاج لخفض ضغط الدم المرتفع.</p><p>لا يوُصف الفوسين&reg;XR ولا يوُصى باستخدامه للنساء والأطفال.</p><p>يتشابه سرطان البروستاتا مع تضخم البروستاتا الحميد في كثير من الأعراض. قبل البدء بالعلاج بالفوسين&reg;XR، سيقوم الطبيب بإجراء فحص عليك للتأكد من وجود سرطان البروستاتا.</p><p>قد يحدث انخفاض ضغط الدم وشعور بالدوار في بداية العلاج &nbsp;خاصةً إذا كنت تستخدم أدوية لخفض ضغط الدم(، وبشكل خاص عند النهوض من وضع الرقاد أو الجلوس. في هذه الحالات، ارقد إلى أن تزول هذه الأعراض تمامًا.</p><p>&nbsp;</p><p><strong>لا تستخدم الفوسين&reg;XR:</strong><br />في حالة الإصابة برد فعلي تحسسي تجاه مادة ألفوزوسين هيدروكلوريد أو أي مكون آخر في الدواء الفوسين&reg;XR(انظر القسم &laquo;ا<strong>لمكونات غير الدوائية المهمة</strong>&raquo; أدناه).</p><p>في حال الانخفاض المتوسط إلى الشديد في وظائف الكبد.</p><p>في حالة تناول أدوية حاصرات ألفا أخرى لعلاج ضغط الدم المرتفع أو مشكلات البروستاتا.</p><p>في حالة تناول أدوية كيتوكونازول، وريتونافير أو إتراكونازول.</p><p>&nbsp;</p><p><strong>استخدم الفوسين&reg;XR بحرص:</strong></p><ul><li dir="rtl">أخبر الطبيب أو الصيدلي قبل استخدام الدواء في الحالات التالية:</li><li dir="rtl">إذا كنت تعاني من مشكلات في الكبد أو الكلى&nbsp;</li><li dir="rtl">إذا كنت تعاني من مشكلات في القلب&nbsp;</li><li dir="rtl">إذا حدث رد فعل لمكونات هذا الدواء&nbsp;</li><li dir="rtl">إذا حدث انخفاض ضغط الدم أو علامات عليه (إغماء، دوار) بعد تناول أدوية أخرى</li><li dir="rtl">إذا كنت مصابًا - أو أحد أفراد عائلتك - بحالة تسُمى تطاول المسافة &nbsp;الخلقي QT</li><li dir="rtl">إذا كنت عانيت من تطاول مسافة QT عقب تناول أي دواء</li><li dir="rtl">إذا كان لديك تاريخ مرضي عائلي بحالة الموت المفاجئ في عمر أصغر من 50 سنة</li><li dir="rtl">إذا كنت عانيت من اضطرابات الإلكتروليتات</li></ul><p>إذا كنت ستخضع لجراحة في العين، فيجب إخبار جراح العيون أنك تستخدم الفوسين&reg;XR في الوقت الحالي.</p><p>&nbsp;</p><p><strong>استخدام أدوية أخرى، أو أعشاب أو مكملات غذائية:</strong><br />يتم أيض الفوسين&reg;XR بواسطة إنزيمات خاصة في الكبد. ليس معروفًا كيف يمكن أن يؤثر استخدام مجموعة أدوية، أو منتجات أعشاب يتم أيضها بواسطة الإنزيمات نفسها، أو بواسطة عصير الليمون الهندي &nbsp;)جريب فروت(، أو على<br />الفعالية أو الآثار الجانبية غير المرغوب فيها لتلك العقاقير أو الأدوية العشبية.</p><p>قبل استخدام أي وصفة طبية، أو أدوية بدون وصفة طبية أو منتجات عشبية، يجب استشارة الطبيب أو الصيدلي.</p><p>&nbsp;</p><p><strong>الأدوية التي تتفاعل مع الفوسين&reg;XR تشمل:</strong></p><ul><li>حاصرات ألفا لعلاج ضغط الدم المرتفع أو مشكلات البروستاتا&nbsp;</li><li>الأدوية المضادة للعدوى: كيتوكونازول، إتراكونازول وريتونافير</li><li>أدوية ضغط الدم المرتفع&nbsp;</li><li>أدوية أمراض القلب (النترات)</li><li>سلدينافيل</li></ul><p>&nbsp;</p><p><strong>استخدام الفوسين&reg;XR مع الطعام والشراب:</strong><br />يجب تناول الفوسين&reg;XR بعد وجبة من الطعام.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة:</strong><br />الفوسين&reg;XR غير موصوف للإستخدام من قبل النساء</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات الثقيلة:</strong><br />قد يشعر بعض الرجال بالدوخة أوالضعف بعد تناول الفوسين&reg;XR. على الرغم من أن هذه الأعراض مستبعدة، فإنه يجب تجنب القيادة أو ممارسة المهام الخطرة اذا حدث هذا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة العادية:</strong><br />اتبع إرشادات الطبيب المتعلقة بطريقة استخدام الفوسين&reg;XR بعناية تامة.&nbsp;</p><p>الجرعة الموصى بها هي قرص واحد ) 10 ملجم( يوميًا يؤخذ مباشرة بعد الوجبة نفسها كل يوم أو من اليوم الأول من تركيب القسطرة. يجب ابتلاع القرص كاملاً.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>لا تمضغ القرص ولا تسحنه ولا تسحقه ولا تطحنه ولا تطحنه بأسنانك لأن ذلك قد يؤدي إلى ارتفاع مستويات الفوسين&reg;XR &nbsp;في الدم.</strong></p></td></tr></tbody></table><p>إذا حدث توقف في العلاج لمدة عدة أيام أو أكثر، فينبغي استئناف استخدام العلاج بعد استشارة الطبيب.</p><p>&nbsp;</p><p><strong>الجرعة الزائدة:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>في حالة تناول جرعة زائدة، اتصل بالطبيب أو قسم الطوارئ بالمستشفى أو مركز مكافحة السموم الأقليمي</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>في حالة تناول جرعة كبيرة جدًا من الفوسين&reg;XR، يجب الذهاب إلى الطبيب على الفور أو الذهاب إلى أقرب مستشفى بها قسم طوارئ. أحضر عبوة الدواء معك وأظهرها للطبيب. افعل هذا حتى لو لم تظهر عليك أي علامات التعب أو التسمم. قد تؤدي الجرعة الزائدة من ألفوزوسين إلى انخفاض ضغط الدم.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>الآثار الجانبية وكيفية التعامل معها:</strong><br />مثل كل الأدوية، قد يسبب الفوسين&reg;XR آثارًا جانبية. معظم هذه الآثار الجانبية بسيطة. قد تشمل الآثار الجانبية لالفوسين&reg;XR الدوار والصداع. في بعض الحالات، قد تقل الآثار الجانبية أو تزول حتى مع الاستمرار في تناول الفوسين&reg;XR.</p><p>قد يشعر المريض بالدوار أو الإغماء بسبب انخفاض ضغط الدم عقب تناول الفوسين&reg;XR. ورغم ذلك، تكون الآثار الجانبية عابرة عادةً، وتحدث في بداية تناول العلاج ولا تستلزم إيقاف العلاج عادة. في هذه الحالات، ارقد إلى أن تزول هذه الأعراض تمامًا. على الرغم من أن هذه الأعراض نادرة الحدوث، يجب تجنب قيادة المركبات أو تشغيل الآلات أو القيام بالمهام الخطرة لمدة 12 ساعة بعد الجرعة الأولي.</p><p>لوحظ حدوث حالات اضطراب الكبد في المرضى الذين يتناولون ألفوزوسين هيدروكلوريد. يجب عليك إبلاغ الطبيب إذا كنت تعاني من أعراض مثل التعب والغثيان واليرقان)اصفرار لون الجلد و/أو العينين( والبول الداكن والبراز فاتح اللون والحكة العامة أو ألم في البطن.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p dir="RTL"><strong>الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td rowspan="2" colspan="2"><p dir="RTL"><strong>العرض/الآثر</strong></p></td><td colspan="2"><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td rowspan="2"><p dir="RTL"><strong>توقف عن تناول الدواء واتصل بالطبيب أو الصيدلي</strong></p></td></tr><tr><td><p dir="RTL"><strong>في الحالات الخطرة فقط</strong></p></td><td><p dir="RTL"><strong>في كل الحالات</strong></p></td></tr><tr><td rowspan="2"><p dir="RTL"><strong>شائعة</strong></p></td><td><p dir="RTL">صداع</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">دوار</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p dir="RTL"><strong>غير شائعة</strong></p></td><td><p dir="RTL">إغماء</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p dir="RTL">مرض الكبد</p></td><td><p>&nbsp;</p></td><td><p dir="RTL">✔</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>وهذه ليست قائمة كاملة بكل الآثار الجانبية. في حالة حدوث أي آثار غير متوقعة أثناء تناول الدواء الفوسين&reg;XR، اتصل بالطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تخزين أقراص الفوسين&reg;XR &nbsp;في درجة حرارة الغرفة أقل من 30 درجة مئوية.</p><p>احفظ الفوسين&reg;XR بعيدًا عن متناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المكوِّن الدوائي:</strong><br />ألفوزوسين هيدروكلوريد.</p><p>&nbsp;</p><p><strong>ما هي المكونات غير الدوائية المهمة:</strong><br />هيدروكسي بروبيل ميثيل سيلولوز، بوليفينيل اسيتيت فاثليت، ستيرات ماغنسيوم دايهيدرات فوسفات كالسيوم ثنائي القاعدة، أكسيد حديد أصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص ممتدة المفعول. يحتوي كل قرص على 10 ملجم من ألفوزوسين هيدروكلوريد.<br />أقراص صفراء، مستديرة، مسطحة الوجه، مشطوفة الحواف، محفور عليها &laquo;APO&raquo; على جانب و &laquo;ALF&raquo; فوق &laquo;10&raquo; على الجانب الآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in GCC: Alfosin® XR

Trade Name in Country of Origin: Apo-Alfuzosin
Generic Name: Alfuzosin Hydrochloride
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Component and Quality Standard 
(and Grade, if applicable)	                                        Function of Component	%w/w	Quantity per unit (mg/tablet)
Alfuzosin Hydrochloride EP	                                                 Active	                  4.167	            10.0
Hydroxypropyl Methylcellulose 2208 K4M USP	      Release- controlling 
                                                                                                        Polymer	                  53.33	           128.0
Polyvinyl Acetate Phthalate NF	                             Release-controlling 
                                                                                                       Polymer	                  33.33	            80.0
Dibasic Calcium Phosphate, Dihydrate USP	                  Diluent/ Filler	           8.33	            20.0
Magnesium Stearate NF	                                                     Lubricant	                  0.583	              1.4
Yellow Ferric Oxide NF	                                                      Colorant	                  0.250	             0.6
TOTAL	                                                                                                                          100.0	           240.0

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged Release Tablets – 10mg

Description of tablet: Yellow, round, flat-faced, beveled-edge tablets. Engraved "APO" on one side, "ALF" over "10" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-ALFUZOSIN (alfuzosin hydrochloride) is indicated for:</p><ul><li>Benign Prostatic Hyperplasia</li></ul><p><strong>&nbsp;</strong></p><p>APO-ALFUZOSIN is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).</p><ul><li>Acute Urinary Retention</li></ul><p><strong>&nbsp;</strong></p><p>APO-ALFUZOSIN is indicated as adjunctive therapy with urethral catheterization for Acute Urinary Retention related to BPH and management following catheter removal.</p><p>&nbsp;</p><p><strong>Geriatrics (&gt;65 years of age):</strong></p><p>Alfuzosin hydrochloride has been found to be safe and effective when administered at the therapeutic dose (10 mg once-daily) to patients over the age of 65 years.</p><p>&nbsp;</p><p><strong>Women:</strong></p><p>APO-ALFUZOSIN is not indicated nor recommended for use in women.</p><p>&nbsp;</p><p><strong>Pediatrics (&lt;18 years):</strong></p><p>APO-ALFUZOSIN is not indicated for use in children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Recommended Dose and Dosage Adjustment</u></p><p><strong>Benign Prostatic Hyperplasia: </strong>The recommended dosage is one 10 mg APO-ALFUZOSIN (alfuzosin hydrochloride) tablet daily to be taken after the same meal each day.</p><p><strong>Acute Urinary Retention: </strong>The recommended dosage is one 10 mg APO-ALFUZOSIN tablet daily after a meal to be taken from the first day of catheterization and continued beyond catheter removal unless there is a relapse of acute urinary retention or disease progression.</p><p>&nbsp;</p><p><u>Administration</u></p><p>The tablet should be swallowed whole. Any other mode of administration, such as crunching, crushing, chewing, grinding or pounding to powder should be prohibited. These actions may lead to an inappropriate release and absorption of the drug and therefore possible early adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ALFUZOSIN (alfuzosin hydrochloride) is contraindicated in:

Patients with a known hypersensitivity to APO-ALFUZOSIN or to any ingredient in the formulation. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.

Patients with moderate to severe hepatic insufficiency, since alfuzosin blood levels are increased in these patients (See 5.2, Special Populations and Conditions, Hepatic Insufficiency).

Combination with other alpha1-blockers.
Combination with potent CYP3A4 inhibitors such as ketoconazole, ritonavir and itroconazole, because alfuzosin blood levels and exposure (AUC) are increased (See 4.5, Overview).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Prostatic carcinoma: Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently coexist. Therefore, patients thought to have BPH should be examined prior to starting therapy with APO-ALFUZOSIN (alfuzosin hydrochloride) to rule out the presence of carcinoma of the prostate.</p><p>&nbsp;</p><p>Patients with known hypersensitivity to alpha1-blockers should be closely monitored while on APO-ALFUZOSIN.</p><p>&nbsp;</p><p>There are no data available on the effect on driving vehicles. Adverse reactions such as vertigo, dizziness and asthenia may occur essentially at the beginning of treatment. This has to be taken into consideration when driving vehicles and operating machines.</p><p>&nbsp;</p><p>Patient should be warned that the tablet should be swallowed whole. Any other mode of administration, such as crunching, crushing, chewing, grinding or pounding to powder should be prohibited. These actions may lead to inappropriate release and absorption of the drug and therefore possible early adverse reactions (see 4.2, Administration).</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p><strong><u>APO-ALFUZOSIN </u></strong><strong><u>is not indicated for the treatment of hypertension.</u></strong></p><p>&nbsp;</p><p>As with all alpha1-blockers in some patients, in particular, patients receiving antihypertensive medications, postural hypotension with or without dizziness or other symptoms may develop within a few hours following administration of APO-ALFUZOSIN. However, these effects are usually transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. In such cases, the patients should lie down until the symptoms have completely disappeared. <strong>As with other alpha1-blockers (alpha1-adrenergic blocking agents), there is a potential for syncope. Patients beginning treatment should be warned of the possible occurrence of such events.</strong></p><p>Care should be taken when APO-ALFUZOSIN is administered to patients with symptomatic orthostatic hypotension or patients who have had a pronounced hypotensive response to another alpha1-blocker.</p><p>&nbsp;</p><p>As with all alpha1-blockers, alfuzosin has been observed to increase heart rate. Caution should be taken in patients with histories of tachyarrhythmia or with certain cardiovascular conditions, such as myocardial ischemia. The heart rate increasing effects of alfuzosin are additive to those of other heart rate increasing drugs (see 4.5).</p><p>&nbsp;</p><p><strong>Coronary insufficiency:</strong></p><p>Specific treatment for coronary insufficiency should be continued; however, if angina pectoris reappears or becomes worse, APO-ALFUZOSIN should be discontinued.</p><p>&nbsp;</p><p>Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of alfuzosin.</p><p>&nbsp;</p><p>Co-administration of alfuzosin with a drug known to be a QTc prolonging drug should be evaluated by the physician based on individual patient&rsquo;s condition (See 5.1, Pharmacodynamics, Electrocardiography).</p><p>&nbsp;</p><p><u>Ophthalmologic</u></p><p>Intraoperative Floppy Iris Syndrome (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with some alpha-1-blockers.</p><p>&nbsp;</p><p>Cases of IFIS have been observed with alfuzosin hydrochloride use. &nbsp;Ophthalmic surgeons should be informed in advance of cataract surgery of current or past use of alpha-1-blockers, as IFIS may lead to increased procedural complications.&nbsp; The ophthalmologists should be prepared for possible modifications to their surgical technique.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><strong>Pregnant Women:</strong></p><p>APO-ALFUZOSIN is not indicated nor recommended for use in women. No embryotoxic and/or teratogenic effects in the rat and rabbit were observed with alfuzosin hydrochloride. Parameters of male and female fertility, parturition, lactation and pup development were not modified by alfuzosin hydrochloride.</p><p>&nbsp;</p><p><strong>Nursing Women:</strong></p><p>APO-ALFUZOSIN is not indicated nor recommended for use in women. It is unknown if the drug is excreted in human milk.</p><p>&nbsp;</p><p><strong>Pediatrics (&lt;18 years):</strong></p><p>APO-ALFUZOSIN is not indicated for use in children.</p><p>&nbsp;</p><p><strong>Geriatrics (&gt;65 years of age):</strong></p><p>The pharmacokinetics parameters (Cmax&nbsp;and AUC) are not increased in elderly patients when compared to healthy male volunteers. Alfuzosin hydrochloride has been found to be a safe and effective &nbsp;alpha1-blockers when administered at the therapeutic dose (10 mg once-daily) to patients over the age of 65 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Overview</u></p><p>APO-ALFUZOSIN (alfuzosin hydrochloride) is not an inducer or an inhibitor of any of the principal hepatic enzymes involved in the metabolism of other drugs.</p><p>CYP3A4 is the principal hepatic enzyme isoform involved in the metabolism of APO- ALFUZOSIN.</p><p>Potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and ritonavir, increased alfuzosin hydrochloride blood levels and exposure (AUC). &nbsp;Therefore, APO-ALFUZOSIN should not be co-administered with potent inhibitors of CYP3A4 (See CONTRAINDICATIONS). <strong>See Drug- Drug Interactions for details of increased alfuzosin hydrochloride blood levels. As this is only a partial list, the physician is advised to consult current scientific literature regarding other CYP 3A4 competitive inhibitors prior to prescribing APO-ALFUZOSIN if other concomitant medications are used as high blood levels of APO-ALFUZOSIN can result.</strong></p><p>It is not known how combined exposure of any medications metabolized by the CYP3A4 hepatic enzyme isoform (such as modern alpha1-blockers), herbal remedies (particularly St. John&rsquo;s Wort, Milk thistle) and grapefruit juice may influence the overall efficacy and unwanted side effects of these medications, therefore, caution should be exercised.</p><p>APO-ALFUZOSIN should be prescribed carefully in combination with antihypertensive drugs (see 4.4, Cardiovascular and Drug-Drug Interactions, Cardiovascular Drugs).</p><p>&nbsp;</p><p><u>Drug-Drug Interactions</u></p><p><strong>Anti-Infectious</strong><strong> Drugs</strong></p><p><u>Imidazole</u></p><p>&nbsp;</p><p><em>Ketoconazole</em></p><p>CYP3A4 is the principal hepatic enzyme involved in the metabolism of APO-ALFUZOSIN. Ketoconazole is a strong-potency inhibitor of CYP3A4. Repeated 200 mg daily dosing of ketoconazole, for seven days <strong>increased alfuzosin hydrochloride C</strong><strong>max</strong><strong>&nbsp;</strong><strong>2.11-fold and AUC</strong><strong>last</strong><strong>&nbsp;</strong><strong>2.46-fold following a single 10 mg dose of alfuzosin hydrochloride </strong>under fed condition. Other parameters such as tmax&nbsp;and t1/2&nbsp;were not modified. The 8-day repeated administration of ketoconazole 400 mg daily <strong>increased C</strong><strong>max</strong><strong>&nbsp;</strong><strong>of alfuzosin hydrochloride by 2.3-fold, AUC</strong><strong>last </strong><strong>and AUC by 3.2 and 3.0 respectively</strong>.</p><p>&nbsp;</p><p><strong>Cardiovascular Drugs</strong></p><p><u>Alpha1-Blocker</u></p><p>APO-ALFUZOSIN should not be used in combination with other alpha1-blockers (see 4.3). <u>Anticoagulant</u></p><p>&nbsp;</p><p><em>Warfarin</em></p><p>The potential drug interactions of alfuzosin hydrochloride with warfarin were studied in clinical trials. The results showed that alfuzosin hydrochloride can be prescribed without risk of interactions in combination with warfarin.</p><p>&nbsp;</p><p><u>Beta-Blocker</u></p><p><em>Atenolol</em></p><p>The potential drug interactions of alfuzosin hydrochloride with atenolol were studied in clinical trials. The results showed that alfuzosin hydrochloride may be used with atenolol taking into account the hypotensive effects specific to drugs in this group.</p><p>&nbsp;</p><p><u>Calcium Channel Blocker</u></p><p><em>Diltiazem</em></p><p>Repeated coadministration of 240 mg/day of diltiazem, a moderate-potency inhibitor of CYP3A4, with 7.5 mg/day alfuzosin (equivalent to the exposure with alfuzosin hydrochloride prolonged-release tablets) increased the Cmax&nbsp;and AUC0-24&nbsp;of alfuzosin 1.5- and 1.3-fold, respectively. Alfuzosin increased the Cmax&nbsp;and AUC0-12&nbsp;of diltiazem 1.4-fold. No changes in blood pressure were observed.</p><p>&nbsp;</p><p><u>Cardiotonic Glycoside</u></p><p><em>Digoxin</em></p><p>Repeated coadministration of alfuzosin hydrochloride and digoxin for 7 days did not influence the steady-state pharmacokinetics of either drug.</p><p>&nbsp;</p><p><u>Diuretic</u></p><p><em>Hydrochlorothiazide</em></p><p>The potential drug interactions of alfuzosin hydrochloride with hydrochlorothiazide were studied in clinical trials. The results showed that alfuzosin hydrochloride can be prescribed without risk of interactions in combination with hydrochlorothiazide.</p><p>&nbsp;</p><p><u>Nitrates</u></p><p>APO-ALFUZOSIN should be prescribed carefully in combination with nitrates.</p><p>&nbsp;</p><p><strong>Gastrointestinal Drugs</strong></p><p><u>Histamine H</u><u>2</u><u>&nbsp;Receptor Antagonist</u></p><p><em>Cimetidine</em></p><p>The potential drug interactions of alfuzosin hydrochloride with cimetidine were studied in clinical trials. The results showed that alfuzosin hydrochloride can be prescribed without risk of interactions in combination with cimetidine.</p><p>&nbsp;</p><p><strong>Sexual Function Drugs</strong></p><p><u>Inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)</u></p><p><em>Tadalafil</em></p><p>The potential drug interaction of alfuzosin hydrochloride with tadalafil was studied in a clinical trial. The results showed that there is no clinically significant hemodynamic interaction between alfuzosin hydrochloride 10 mg once daily and tadalafil 20 mg. APO-ALFUZOSIN can be prescribed in combination with tadalafil.</p><p>&nbsp;</p><p><em>Sildenafil</em></p><p>The effect on QT/QTc interval of the combination of alfuzosin 10 mg and sildenafil 100 mg has been studied in an electrophysiology trial (See 5.1, Pharmacodynamics, Electrocardiography).</p><p>&nbsp;</p><p><u>Drug-Food Interactions</u></p><p>APO-ALFUZOSIN should be taken after a meal.</p><p>&nbsp;</p><p>It is not known how combined exposure of grapefruit juice may influence the overall efficacy and unwanted side effects of these types of medications, therefore, caution should be exercised.</p><p>&nbsp;</p><p><u>Drug-Herb Interactions</u></p><p>Interactions with herbal products have not been established. It is not known how combined exposure of herbal remedies (particularly St. John&rsquo;s Wort, Milk thistle) may influence the overall efficacy and unwanted side effects of these medications, therefore, caution should be exercised when taking herbal remedies with these types of medications.</p><p>&nbsp;</p><p><u>Drug-Laboratory Interactions</u></p><p>Treatment with alfuzosin hydrochloride for up to 12 months produced no clinically significant changes in urinalysis, the routine biochemical and hematologic tests as well as in prostate specific antigen (PSA).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alfuzosin is not indicated for women. For more details concerning fertility, see Toxicology under 5.4</p><p>&nbsp;</p><p>Pregnancy Category: B</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients may experience dizziness or fainting caused by a decrease in blood pressure after taking APO-ALFUZOSIN.&nbsp; However, these effects are usually transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. &nbsp;In such cases, patients should lie down until the symptoms have completely disappeared. &nbsp;Although these symptoms are unlikely, patients should not drive, operate machinery or perform hazardous tasks for 12 hours after the initial dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adverse Drug Reaction Overview</u></p><p>Dizziness and headache are the most frequent adverse drug reactions with alfuzosin hydrochloride.</p><p>Alfuzosin hydrochloride was associated with a low incidence of postural symptoms. As with all alpha1-blockers, there is also a potential for syncope.</p><p>Alfuzosin hydrochloride was not associated with deleterious effects on sexual function.</p><p>&nbsp;</p><p><u>Clinical Trial Adverse Drug Reactions</u></p><p><em>Because</em><em> </em><em>clinical</em><em> trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug.&nbsp; Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.</em></p><p>Safety information was derived from placebo-controlled clinical trials involving 1,608 men with BPH. The safety profile of alfuzosin hydrochloride in the ALFAUR study which included 363 patients with Acute Urinary Retention due to BPH was similar to the safety profile reported in previous BPH studies.</p><p>&nbsp;</p><p>In the BPH studies, 4% of patients taking alfuzosin hydrochloride 10 mg prolonged release tablets withdrew from the study due to adverse events, compared with 3% in the placebo group. Dizziness and headache were the most frequent cause in each of the groups, although no single symptom was predominant. The withdrawal rate was similar in the alfuzosin hydrochloride group following long-term use in open-label extension studies for up to 1 year.</p><p>&nbsp;</p><p>Table 1 summarizes the treatment-emergent adverse events that occurred in &ge;2% of patients receiving alfuzosin hydrochloride prolonged-release tablets and placebo, in three 3-month trials. In general, the adverse events seen in long-term use were similar in type and frequency to the events described below for the 3-month trials.</p><p>&nbsp;</p><p><strong>Table 1 &ndash; Treatment-Emergent Adverse Events Occurring in &ge;2% of Patients with BPH treated with Alfuzosin Hydrochloride and with Placebo in 3-Month Placebo-Controlled Clinical Studies</strong></p><table align="left" style="width:634px" border="1" cellspacing="1" cellpadding="3"><tbody><tr><td style="width:379px"><p><strong>Adverse Event</strong></p></td><td style="width:95px"><p><strong>Placebo (N=678)</strong></p></td><td style="width:157px"><p><strong>Alfuzosin Hydrochloride (N=473)</strong></p></td></tr><tr><td style="width:633px" colspan="3"><p><strong>General Disorders and Administration Site Conditions</strong></p></td></tr><tr><td style="width:379px"><p>Fatigue*</p></td><td style="width:95px"><p>12 (1.8%)</p></td><td style="width:157px"><p>13 (2.7%)</p></td></tr><tr><td style="width:633px" colspan="3"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and Connective</strong><strong> Tissue Disorders</strong></p></td></tr><tr><td style="width:379px"><p>Joint Disorders**</p></td><td style="width:95px"><p>15 (2.2%)</p></td><td style="width:157px"><p>10 (2.1%)</p></td></tr><tr><td style="width:633px" colspan="3"><p><strong>Infection and Infestations</strong></p></td></tr><tr><td style="width:379px"><p>Upper respiratory tract infection***</p></td><td style="width:95px"><p>23 (3.4%)</p></td><td style="width:157px"><p>29 (6.1%)</p></td></tr><tr><td style="width:379px" colspan="3"><p><strong>Nervous</strong><strong> System Disorders</strong></p></td></tr><tr><td style="width:379px"><p>Dizziness****</p></td><td style="width:95px"><p>19 (2.8%)</p></td><td style="width:157px"><p>27 (5.7%)</p></td></tr><tr><td style="width:379px"><p>Headache</p></td><td style="width:95px"><p>12 (1.8%)</p></td><td style="width:157px"><p>14 (3.0%)</p></td></tr></tbody></table><table style="width:633px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:632px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:632px"><p>*Includes: fatigue and asthenia</p><p>**Includes: arthritis, arthrosis, arthropathy, arthritis aggravated, arthralgia, and bursitis</p><p>***Includes: upper respiratory tract infection, rhinitis, sinusitis, laryngitis, pharyngitis</p><p>****Includes: dizziness and malaise</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>Less</u></strong><strong><u> Common Clinical Trial Adverse Drug Reactions (&lt;1%)</u></strong></p><p>The following adverse events, reported by between 1% and 2% of patients receiving alfuzosin hydrochloride prolonged-release tablets and placebo are listed and are as follows:</p><p>&nbsp;</p><p><strong>Table 2 &ndash; Treatment-Emergent Adverse Events Occurring Between 1% and 2% of Patients with BPH treated with Alfuzosin Hydrochloride Prolonged-release Tablets and Placebo in 3-Month Placebo-Controlled Clinical Studie</strong></p><table style="width:485px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Event</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<strong> </strong>(N=678)</strong></p></td><td style="vertical-align:top; width:216px"><p><strong>Alfuzosin</strong><strong> </strong><strong>Hydrochloride</strong><strong> </strong><strong>(N=473)</strong></p></td></tr><tr><td style="vertical-align:top; width:485px" colspan="3"><p><strong>Gastrointestinal</strong><strong> </strong><strong>Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>7 (1.0)</p></td><td style="vertical-align:top; width:216px"><p>7 (1.5)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>7 (1.0)</p></td><td style="vertical-align:top; width:216px"><p>6 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>3 (0.4)</p></td><td style="vertical-align:top; width:216px"><p>5 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top; width:216px"><p>5 (1.1)</p></td></tr><tr><td style="vertical-align:top; width:485px" colspan="3"><p><strong>General</strong><strong> </strong><strong>Disorders</strong><strong> and Administration Site</strong>&nbsp;<strong>Conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top"><p>14 (2.1)</p></td><td style="vertical-align:top; width:216px"><p>9 (1.9)</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top; width:216px"><p>7 (1.5)</p></td></tr><tr><td style="vertical-align:top; width:485px" colspan="3"><p><strong>Infection and Infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>5 (0.7)</p></td><td style="vertical-align:top; width:216px"><p>7 (1.5)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="3"><p><strong>Injury,</strong><strong> </strong><strong>Poisoning</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Procedural</strong><strong> </strong><strong>Complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Inflicted injury*</p></td><td style="vertical-align:top"><p>3 (0.4)</p></td><td style="vertical-align:top"><p>6 (1.3)</p></td></tr><tr><td style="vertical-align:top" colspan="2"><p><strong>Musculoskeletal</strong><strong> </strong><strong>and Connective</strong><strong> Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Back pain**</p></td><td style="vertical-align:top"><p>11(1.6)</p></td><td style="vertical-align:top"><p>7 (1.5)</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p><strong>Reproductive</strong><strong> </strong><strong>System</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Breast</strong><strong> </strong><strong>Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Impotence</p></td><td style="vertical-align:top"><p>4 (0.6)</p></td><td style="vertical-align:top"><p>7 (1.5)</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p>*Includes: bite and inflicted injury</p></td></tr><tr><td style="vertical-align:top" colspan="3"><p>**Includes: ischial neuralgia, neuralgia, neuropathy, back pain, and lumbar disc lesion</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Reproductive </strong><strong>System and Breast Disorders</strong></p><p>Impotence and other events related to sexual function are commonly associated with other alpha1-blockers, however, with alfuzosin hydrochloride, there were minimal effects regarding sexual function and ejaculatory disorders/abnormalities with no reports of priapism. Also, no patient discontinued treatment with alfuzosin hydrochloride due to ejaculation disorders. The reported incidence of ejaculation disorders was not associated with the study drug and is consistent with that reported in the untreated population.</p><p>&nbsp;</p><p><strong>Vascular Disorders</strong></p><p><u>Signs and Symptoms of Orthostasis in Clinical Studies</u></p><p>The number of patients with symptoms of orthostasis are summarized in Table 3.</p><p><strong>Table 3 &ndash; Number (%) of Patients with BPH with Symptoms Possibly Associated with Orthostasis in 3-Month Placebo-Controlled Clinical Studies</strong></p><table style="width:553px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:236px"><p><strong>Symptoms</strong></p></td><td style="vertical-align:top; width:79px"><p><strong>Placebo<strong> </strong>(N=678)</strong></p></td><td style="vertical-align:top; width:234px"><p><strong>Alfuzosin</strong><strong> </strong><strong>Hydrochloride Prolonged-release Tablets</strong><strong>&nbsp;</strong><strong>(N=473)</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Dizziness</p></td><td style="vertical-align:top; width:79px"><p>19 (2.8%)</p></td><td style="vertical-align:top; width:234px"><p>27 (5.7%)</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Hypotension or postural hypotension</p></td><td style="vertical-align:top; width:79px"><p>0</p></td><td style="vertical-align:top; width:234px"><p>2 (0.4%)</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Syncope</p></td><td style="vertical-align:top; width:79px"><p>0</p></td><td style="vertical-align:top; width:234px"><p>1 (0.2%)</p></td></tr></tbody></table><p>&nbsp;</p><p>Multiple testing for blood pressure changes or orthostatic hypotension was conducted in the three controlled studies. These tests were considered positive for blood pressure decrease if (1) supine systolic blood pressure was &le; 90 mmHg, with a decrease &ge; 20 mmHg versus baseline, and/or (2) supine diastolic blood pressure was &le; 50 mmHg, with a decrease &ge; 15 mmHg versus baseline.</p><p>The tests were considered positive for orthostatic hypotension if there was a decrease in systolic blood pressure of &ge; 20 mmHg upon standing from the supine position during the orthostatic tests. The percentage of patients with a positive test at any visit was 7.7% for placebo and 6.6% for alfuzosin hydrochloride prolonged-release tablets, as shown in Table 4.</p><p>&nbsp;</p><p><strong>Table 4 &ndash; Number (%) of Patients with BPH with Clinically Meaningful Decreases in Blood Pressure at Any Visit in 3-Month Placebo-Controlled Clinical Studies</strong></p><table style="width:553px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:236px"><p><strong>Clinically</strong><strong> </strong><strong>Meaningful</strong><strong> </strong><strong>Change</strong></p></td><td style="vertical-align:top; width:79px"><p><strong>Placebo<strong> </strong>(N=674)</strong></p></td><td style="vertical-align:top; width:234px"><p><strong>Alfuzosin</strong><strong> </strong><strong>Hydrochloride Prolonged-release Tablets</strong><strong>&nbsp;</strong><strong>(N=469)</strong></p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Decreased systolic blood pressure</p></td><td style="vertical-align:top; width:79px"><p>0</p></td><td style="vertical-align:top; width:234px"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Decreased diastolic blood pressure</p></td><td style="vertical-align:top; width:79px"><p>3 (0.4%)</p></td><td style="vertical-align:top; width:234px"><p>4 (0.9%)</p></td></tr><tr><td style="vertical-align:top; width:236px"><p>Positive orthostatic test</p></td><td style="vertical-align:top; width:79px"><p>52 (7.7%)</p></td><td style="vertical-align:top; width:234px"><p>31* (6.6%)</p></td></tr></tbody></table><p>*N = 471</p><p>&nbsp;</p><p>A subset of patients from Study 1 had blood pressure measurements 12 to 16 hours after the first dose to assess the potential to produce orthostatic hypotension. None of the 35 alfuzosin hydrochloride prolonged release tablet-treated patients showed a positive test for systolic, diastolic, or orthostatic blood pressure change.</p><p>&nbsp;</p><p>No age effect on the overall incidence of patients reporting adverse events was observed in the alfuzosin hydrochloride prolonged-release tablet group; elderly patients (&ge; 65 years) did not experience more vasodilatory adverse events than the younger patients.</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>The following adverse events have also been reported in post-marketing experience:</p><p>The following frequency rating is used; very common (&ge; 10%), Common (&ge; 1% and &lt; 10%), Uncommon (&ge; 0.1% and &lt; 1%), Rare (&ge; 0.01% and &lt; 0.1%), Very rare (&lt; 0.01%)</p><p>&nbsp;</p><p><strong>Cardiac Disorders</strong>:</p><p>Uncommon: tachycardia</p><p>Very Rare: angina pectoris in patients with pre-existing coronary artery disease (see also 4.4, Cardiovascular). &nbsp;Isolated spontaneous cases of QT interval prolongation, ventricular arrhythmias, including Torsade de Pointes, ventricular tachycardia and fibrillation have been reported particularly in patients with preexisting cardiovascular diseases; however, a relationship between these adverse events and the alfuzosin hydrochloride treatment was not clearly established due to concomitant cardiac disorders, concomitant medications or absence of pre- treatment ECG measurement.</p><p>&nbsp;</p><p><strong>Vascular Disorders:</strong></p><p>Uncommon: flushing</p><p>&nbsp;</p><p><strong>Gastrointestinal</strong><strong> disorders</strong>:</p><p>Uncommon: diarrhea</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>General</strong><strong> Disorders and Administration Site Conditions</strong>:</p><p>Uncommon: edema, chest pain</p><p>&nbsp;</p><p><strong>Ear and Labyrinth Disorders:</strong></p><p>Uncommon: vertigo</p><p>&nbsp;</p><p><strong>Eye disorders:</strong></p><p>Cases of intraoperative floppy iris syndrome have been reported (see 4.4, Ophthalmologic).</p><p>&nbsp;</p><p><strong>Hepato-biliary disorders:</strong></p><p>Cases of hepatocellular injury and cholestatic liver disease have been reported.</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders:</strong></p><p>Uncommon: Rhinitis.</p><p>&nbsp;</p><p><strong>Skin and Subcutaneous Tissue Disorders:</strong></p><p>Uncommon: rash, pruritus</p><p>Very rare: urticaria, angioedema</p><p>&nbsp;</p><p>- To report any side effects:</p><table style="width:476px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:475px"><p><strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966‐11‐205‐7662</li><li>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</li><li>Toll free phone: 8002490000</li><li>E‐mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>Should overdose of APO-ALFUZOSIN (alfuzosin hydrochloride) lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then the administration of intravenous fluids should be considered. If necessary, vasopressor should then be used and the renal function should be monitored and supported as needed. Alfuzosin hydrochloride is 87% (82 - 90%) protein-bound, therefore, dialysis may not be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Mechanism of Action</u></strong></p><p>APO-ALFUZOSIN (alfuzosin hydrochloride), indicated for the treatment of benign prostatic hyperplasia (BPH) and as adjunctive therapy with urethral catheterization for acute urinary retention related to BPH and management following catheter removal, is a uroselective antagonist of post-synaptic &alpha;1-adrenoceptors located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.</p><p>&nbsp;</p><p><strong><u>Pharmacodynamics</u></strong></p><p>The clinical manifestations of benign prostatic hyperplasia are due to bladder outlet obstruction caused by anatomical (static) and functional (dynamic) factors. The static component is related to an increase in prostate size which may not cause symptoms. The dynamic component is related primarily to an increase in smooth muscle tone in the prostate, prostatic capsule, bladder base, bladder neck, and prostatic urethra. This increased tone is mediated by the activation of &alpha;1- adrenoceptors and leads to an increased resistance to urinary voiding and the symptoms of BPH such as a hesitant, interrupted, weak stream; urgency and leaking or dribbling; and/or more frequent urination, especially at night. Alfuzosin hydrochloride blocks &alpha;1-adrenoceptors leading to a relaxation of the smooth muscle in the bladder neck and prostate.</p><p>In animal studies, alfuzosin was shown to be functionally uroselective by preferentially decreasing urethral blood pressure over arterial blood pressure. In human tissue, <em>in vitro</em>, alfuzosin has induced preferential &alpha;1-adrenoceptor antagonist activity on prostatic cells relative to renal artery cells. This is illustrated in the figure below:</p><p><strong>Figure 1: Prostatic Selectivity Score</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image4.png" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:333.75pt;height:207.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title=""/>
</v:shape><![endif]--><img width="445" height="277" alt="" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p><strong>&nbsp;<img width="468" height="292" alt="" src="data:image/png;base64,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" /></strong></p><p>In placebo-controlled clinical studies in patients with BPH, alfuzosin hydrochloride was shown to:</p><ul><li>significantly increase urine peak flow rate (Qmax) by 30% which is observed after the first dose</li><li>significantly reduce detrusor pressure and increase bladder capacity</li><li>significantly reduce residual urine volume</li></ul><p>These favourable urodynamic effects lead to an improvement of lower tract irritative and obstructive symptoms without any deleterious effect on sexual function. The Quality of Life Index was also significantly improved by 33% in the alfuzosin hydrochloride prolonged-release tablet - treated patients.</p><p>In addition, the efficacy of alfuzosin 10 mg OD on peak flow rate and the limited effect on blood pressure have been demonstrated to be related to its pharmacokinetic profile. Moreover, the efficacy on peak flow rate is maintained up to 24 hours after intake.</p><p>A lower frequency of acute urinary retention was observed in the alfuzosin treated patient than in the untreated patient.</p><p>&nbsp;</p><p><strong>Electrocardiography:</strong></p><p>The effect of 10 mg and 40 mg alfuzosin on QT interval was evaluated in a double-blind, randomized, placebo and active-controlled (moxifloxacin 400 mg), 4-way crossover single dose study in 45 healthy white male subjects aged 19 to 45 years.&nbsp; The 40 mg dose of alfuzosin was chosen because this dose achieves higher blood levels than those achieved with the co- administration of alfuzosin hydrochloride and ketoconazole 400 mg (CYP3A4 inhibitor).&nbsp; QT interval, obtained with 12-lead ECGs, was measured from 2h to 12h post treatment administration.&nbsp; Table 5 summarizes the mean effect and the maximum mean effect on heart rate (HR) and corrected QT interval (QTc) with different methods of correction [Bazett (QTcB), Fridericia (QTcF) and population-specific (QTcN) correction methods].&nbsp; There is a trend to lower values for QTc interval changes from QTcB&agrave; QTcF &agrave; QTcN, demonstrating the critical role of the correction formula used to minimize the biased overestimation linked to the heart rate increase.&nbsp; The maximum mean change of heart rate associated with a 10 mg dose of alfuzosin in this study was 3.69 beats/minute and 5.45 beats/minute with 40 mg alfuzosin.&nbsp; The change in heart rate with moxifloxacin was 2.85 beats/minute.</p><p>&nbsp;</p><p><strong>Table 5: 12-lead ECG &ndash; Mean change in HR and QTc data from T7 &ndash; T11h and maximum mean baseline- and placebo-adjusted HR and QTc interval changes over the observation period T2-T12h</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p><strong>Mean difference</strong></p></td><td style="vertical-align:top" colspan="2"><p><strong>Largest</strong><strong> </strong><strong>time-matched analysis</strong><strong> </strong><strong>(bootstrap adjusted)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline vs placebo</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;95% CI (upper bound)</strong></p></td><td style="vertical-align:top"><p><strong>Estimation </strong><strong>of</strong><strong> </strong><strong>largest</strong><strong> </strong><strong>time-</strong><strong> </strong><strong>matched</strong><strong> </strong><strong>mean difference</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;95% CI (upper bound)</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="3"><p><strong>&nbsp;</strong></p><p><strong>HR (bpm)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>3.69</p></td><td style="vertical-align:top"><p>5.83</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin 40 mg</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>5.45</p></td><td style="vertical-align:top"><p>7.06</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>2.85</p></td><td style="vertical-align:top"><p>4.26</p></td></tr><tr><td style="vertical-align:top" rowspan="3"><p><strong>QTcB</strong></p><p><strong>(msec)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>6.08</p></td><td style="vertical-align:top"><p>9.59</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin 40 mg</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>14.4</p></td><td style="vertical-align:top"><p>13.27</p></td><td style="vertical-align:top"><p>16.71</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>15.6</p></td><td style="vertical-align:top"><p>12.57</p></td><td style="vertical-align:top"><p>16.12</p></td></tr><tr><td style="vertical-align:top" rowspan="3"><p><strong>QTcF</strong></p><p><strong>(msec)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>4.01</p></td><td style="vertical-align:top"><p>6.68</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin 40 mg</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top"><p>10.73</p></td><td style="vertical-align:top"><p>13.49</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>10.3</p></td><td style="vertical-align:top"><p>13.0</p></td><td style="vertical-align:top"><p>11.17</p></td><td style="vertical-align:top"><p>14.06</p></td></tr><tr><td style="vertical-align:top" rowspan="3"><p><strong>QTcN</strong></p><p><strong>(msec)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>2.74</p></td><td style="vertical-align:top"><p>5.27</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin 40 mg</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>9.30</p></td><td style="vertical-align:top"><p>12.14</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>10.78</p></td><td style="vertical-align:top"><p>13.67</p></td></tr></tbody></table><p><strong>*</strong><em>Active control</em></p><p><em>&nbsp;</em></p><p>The maximum mean effect on QTcN appeared greater for 40 mg compared to 10 mg alfuzosin. The effect of the highest alfuzosin dose (four times the therapeutic dose) studied did not appear as large as that of the active control moxifloxacin at its therapeutic dose.</p><p>&nbsp;</p><p>A separate post-marketing study evaluated the effect of the co-administration of 10 mg alfuzosin and a drug with similar QT effect size. &nbsp;It was a double-blind, randomized, placebo and active- controlled (moxifloxacin 400 mg), 5-way crossover study conducted in 39 healthy white male subjects aged 19 to 46 years.&nbsp; QT interval, obtained with 12-lead ECGs, was measured from 4h to 12h post treatment administration. Maximum mean effect on HR and QT interval were extracted from a time-matched placebo adjusted analysis. &nbsp;In this study, the maximum mean placebo-substracted QTcN increase of alfuzosin 10 mg alone was 4.41 msec (upperbound 95% CI, 7.09 msec), shown in Table 6 below. The concomitant administration of the two drugs (alfuzosin and sildenafil) showed an increased QT effect when compared with either drug alone. This maximum mean QTcN increase [8.27 msec (UB 95% CI, 10.90 msec)] was not more than additive.&nbsp; Although this study was not designed to make direct statistical comparisons between drugs, the maximum mean QTcN increase with both drugs given together appeared to be lower than the maximum mean QTcN increase seen with the positive control moxifloxacin 400 mg [11.44 msec (UB 95% CI, 14.01 msec)]. The combination of alfuzosin + sildenafil produced a statistically significant increase in the mean heart rate [+ 4 bpm, p&lt;0.0001].</p><p>&nbsp;</p><p><strong>Table 6: 12-lead ECG &ndash; Mean change in HR and QTc data from T7 &ndash; T10h and maximum mean baseline- and placebo-adjusted HR and QT interval changes over the observation period T4-T12h</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top" colspan="2"><p>&nbsp;</p></td><td style="vertical-align:top" colspan="2"><p><strong>Mean difference</strong></p></td><td style="vertical-align:top" colspan="3"><p><strong>Largest</strong><strong> </strong><strong>time-matched analysis</strong><strong> </strong><strong>(bootstrap adjusted)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p><strong>Mean change from baseline vs placebo</strong></p></td><td style="vertical-align:top" colspan="2"><p><strong>95% CI (upper<strong> </strong>bound)</strong></p></td><td style="vertical-align:top"><p><strong>Estimation </strong><strong>of</strong><strong> </strong><strong>largest</strong><strong> </strong><strong>time-</strong><strong> </strong><strong>matched</strong><strong> </strong><strong>mean difference</strong></p></td><td style="vertical-align:top"><p><strong>95% CI (upper<strong> </strong>bound)</strong></p></td></tr><tr><td style="vertical-align:top" rowspan="4"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>HR (bpm)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top" colspan="2"><p>2.9</p></td><td style="vertical-align:top"><p>3.78</p></td><td style="vertical-align:top"><p>5.54</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin + Sildenafil</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top" colspan="2"><p>5.8</p></td><td style="vertical-align:top"><p>5.53</p></td><td style="vertical-align:top"><p>7.25</p></td></tr><tr><td style="vertical-align:top"><p>Sildenafil 100 mg</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top" colspan="2"><p>3.2</p></td><td style="vertical-align:top"><p>2.13</p></td><td style="vertical-align:top"><p>3.82</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top" colspan="2"><p>3.2</p></td><td style="vertical-align:top"><p>2.80</p></td><td style="vertical-align:top"><p>4.39</p></td></tr><tr><td style="vertical-align:top" rowspan="4"><p><strong>&nbsp;</strong></p><p><strong>QTcB</strong></p><p><strong>(msec)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top" colspan="2"><p>8.8</p></td><td style="vertical-align:top"><p>7.49</p></td><td style="vertical-align:top"><p>10.68</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin + Sildenafil</p></td><td style="vertical-align:top"><p>13.3</p></td><td style="vertical-align:top" colspan="2"><p>17.1</p></td><td style="vertical-align:top"><p>14.99</p></td><td style="vertical-align:top"><p>18.35</p></td></tr><tr><td style="vertical-align:top"><p>Sildenafil 100 mg</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top" colspan="2"><p>10.1</p></td><td style="vertical-align:top"><p>7.85</p></td><td style="vertical-align:top"><p>11.30</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top" colspan="2"><p>13.2</p></td><td style="vertical-align:top"><p>17.18</p></td><td style="vertical-align:top"><p>20.72</p></td></tr><tr><td style="vertical-align:top" rowspan="4"><p><strong>&nbsp;</strong></p><p><strong>QTcF</strong></p><p><strong>(msec)</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top" colspan="2"><p>6.6</p></td><td style="vertical-align:top"><p>5.72</p></td><td style="vertical-align:top"><p>8.19</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin + Sildenafil</p></td><td style="vertical-align:top"><p>9.5</p></td><td style="vertical-align:top" colspan="2"><p>12.4</p></td><td style="vertical-align:top"><p>10.47</p></td><td style="vertical-align:top"><p>12.97</p></td></tr><tr><td style="vertical-align:top"><p>Sildenafil 100 mg</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top" colspan="2"><p>7.7</p></td><td style="vertical-align:top"><p>6.40</p></td><td style="vertical-align:top"><p>8.97</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top" colspan="2"><p>10.7</p></td><td style="vertical-align:top"><p>13.80</p></td><td style="vertical-align:top"><p>16.48</p></td></tr><tr><td style="vertical-align:top" rowspan="4"><p><strong>&nbsp;</strong></p><p><strong>QTcN</strong></p><p><strong>(msec)**</strong></p></td><td style="vertical-align:top"><p>Alfuzosin 10 mg</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top" colspan="2"><p>5.1</p></td><td style="vertical-align:top"><p>4.41</p></td><td style="vertical-align:top"><p>7.09</p></td></tr><tr><td style="vertical-align:top"><p>Alfuzosin + Sildenafil</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top" colspan="2"><p>10.0</p></td><td style="vertical-align:top"><p>8.27</p></td><td style="vertical-align:top"><p>10.90</p></td></tr><tr><td style="vertical-align:top"><p>Sildenafil 100 mg</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top" colspan="2"><p>6.4</p></td><td style="vertical-align:top"><p>5.26</p></td><td style="vertical-align:top"><p>7.87</p></td></tr><tr><td style="vertical-align:top"><p>Moxifloxacin*</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top" colspan="2"><p>9.4</p></td><td style="vertical-align:top"><p>11.44</p></td><td style="vertical-align:top"><p>14.01</p></td></tr></tbody></table><p><strong>*</strong><em>Active control</em></p><p><em>**For</em><em> the analysis of the mean difference, only QTcNi data are available (QT interval corrected by a subject specific formula)</em></p><p><em>&nbsp;</em></p><p>QT interval prolongation has not been studied in patients with BPH, therefore similar data is not available.&nbsp; This population may suffer from other conditions and have a higher risk to develop QT interval prolongation due to concomitant risk factors or pre-existing cardiovascular disorders. Based on individual patient&rsquo;s condition, monitoring for ECG abnormalities should be considered by the physician during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption:</strong></p><p>Bioavailability is reduced when alfuzosin hydrochloride is administered under fasting conditions. A consistent pharmacokinetic profile is obtained when alfuzosin hydrochloride is administered following a meal. A mean peak plasma concentration of 12.3 &plusmn; 6.6 ng/mL is reached in 6 to 14 hours after a single dose.</p><p>Under fed conditions and after repeated doses, mean Cmax&nbsp;and Cthrough values are 13.6 (SD = 5.6) and 3.1 (SD = 1.6) ng/mL respectively. Mean AUC0-24 is 194 (SD = 75) mg.h/mL. A plateau of concentration is observed from 3 to 14 hours with concentrations above 8.1 ng/mL (Cav) for 11 hours.</p><p>&nbsp;</p><p><strong>Figure 2: Mean (SEM) alfuzosin plasma concentration-time profiles after a repeated administration of alfuzosin 10 mg OD tablet in healthy middle-aged male volunteers (N=42)</strong></p><p><strong>&nbsp;</strong></p><p><strong><img width="509" height="315" alt="" src="data:image/png;base64,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" /></strong></p><p><strong>Distribution:</strong></p><p>The volume of distribution calculated following intravenous administration is 2.5 L/kg which indicates a distribution into extracellular fluids of the body. Alfuzosin hydrochloride is moderately bound to plasma proteins with the free fraction accounting for 13.3% in healthy volunteers. Fractions bound to serum albumin and &alpha;1-glycoproteins are 68.2 and 52.5%, respectively. Salicylic acid, hydrochlorothiazide, diltiazem, digoxin and indomethacin do not affect the binding of alfuzosin hydrochloride to human plasma proteins. Based on <em>in vivo </em>data, it is not likely that alfuzosin hydrochloride will affect the extent of binding of these drugs to human plasma proteins. There is an increase in free fraction in renal insufficiency patients (16.8%) and in patients with hepatic disease (20.8%).</p><p>&nbsp;</p><p><strong>Metabolism:</strong></p><p>Alfuzosin hydrochloride undergoes metabolism by the liver, with only 11% of the parent compound being excreted as unchanged in the urine. The metabolites which are all inactive are eliminated in the urine (15-30%) and feces (75-91%). Alfuzosin hydrochloride is metabolized by three metabolic pathways (oxidation, O-demethylation, N&ndash;dealkylation) which are qualitatively identical to those observed in the animal (rat and dog).</p><p>CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.</p><p>&nbsp;</p><p><strong>Excretion:</strong></p><p>Following intravenous or oral administration, the elimination of alfuzosin hydrochloride is characterized, in healthy young subjects and in the target population, by a terminal half-life of about 4.8 hours and a total clearance of 0.3 L/h/kg.</p><p>The apparent half-life of alfuzosin hydrochloride is increased to 9.1 hours in healthy middle-aged volunteers and to 10.1 hours in elderly volunteers.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>&nbsp;Geriatrics:</strong></p><p><strong>&nbsp;</strong>Compared to healthy middle-aged volunteers, the pharmacokinetic parameters of alfuzosin hydrochloride (Cmax&nbsp;and AUC) are not increased in elderly patients.</p><p>&nbsp;</p><p><strong>Renal Insufficiency:</strong></p><p>Compared to subjects with normal renal function, the mean Cmax&nbsp;and AUC values of alfuzosin hydrochloride are moderately increased (1.5 to 1.6 fold) in patients with various stages of renal impairment, with no change in the apparent elimination half-life. This change in the pharmacokinetic profile is not considered clinically relevant; and therefore, does not necessitate a dosing adjustment.&nbsp; Alfuzosin hydrochloride prolonged-release tablet has not been evaluated in patients with end-stage renal disease.</p><p>&nbsp;</p><p><strong>Hepatic Insufficiency:</strong></p><p>After a single oral administration of alfuzosin hydrochloride in patients with severe hepatic insufficiency, the elimination half-life is prolonged. A two-fold increase in Cmax&nbsp;values and a three-fold increase in the AUC is observed. Bioavailability is increased in comparison with that in healthy volunteers (See 4.3).</p><p>&nbsp;</p><p><strong>Chronic Cardiac Insufficiency:</strong></p><p>The pharmacokinetic profile of alfuzosin hydrochloride administered intravenously is not affected by chronic cardiac insufficiency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Acute toxicity</u></strong></p><p>The results of single dose toxicity studies in mice and rats after oral and intraperitoneal administration are summarized in the table 12 below.</p><p><strong>Table 12 - Single dose toxicity studies in mice and rats after oral and intraperitoneal administration</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Species</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Route</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Sex</strong></p></td><td style="vertical-align:top"><p><strong>LD</strong><strong>50</strong><strong>-values</strong><strong> </strong><strong>(mg/kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p>mouse</p></td><td style="vertical-align:top" rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>oral</p></td><td style="vertical-align:top"><p>M &amp; F</p><p>(10, 20, 40, 60</p><p>mice/sex)</p></td><td style="vertical-align:top"><p>2300 + 94 in males</p><p><strong>&nbsp;</strong>1950 &plusmn; 79 in females</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong>rat</p></td><td style="vertical-align:top"><p>M &amp; F</p><p><strong>&nbsp;</strong>(10, 20 rats/sex)</p></td><td style="vertical-align:top"><p>&ge; 4000 in males 3000 in females</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong>mouse</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong>intraperitoneal</p></td><td style="vertical-align:top"><p>M &amp; F</p><p>(20 mice/sex)</p></td><td style="vertical-align:top"><p>600 &plusmn; 25 in males</p><p>650 &plusmn; 20 in females</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong>rat</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>M &amp; F</p><p><strong>&nbsp;</strong>(10, 20 rats/sex)</p></td><td style="vertical-align:top"><p>480 in males and females</p></td></tr></tbody></table><p>&nbsp;</p><p>Clinical symptoms included palpebral ptosis, motor disturbances, sedation, prostration, cyanosis and clonic convulsions. Symptoms disappeared within 4 to 5 days after administration.</p><p>After intravenous administration in mice and rats, no deaths were observed as the maximum deliverable dose under experimental conditions was 40 mg/kg for both mice and rats.</p><p>&nbsp;</p><p><strong><u>Chronic toxicity</u></strong></p><p>The chronic toxicity of orally administered alfuzosin was studied in rats and dogs in 1 month and 3 month toxicity studies. In addition, chronic oral toxicity was evaluated in rats up to 6 months. The dosages administered in these studies are given in the following table.</p><p>&nbsp;</p><p><strong>Table 13 - Chronic 1-month and 3-month toxicity studies in rats and dogs.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;Study</strong></p></td><td style="vertical-align:top"><p><strong>Alfuzosin</strong><strong> </strong><strong>doses</strong><strong> in mg/kg/day (Oral administration)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1 week intravenous study in rats</p><p>(5M, 5F/dose group)</p></td><td style="vertical-align:top"><p>30, 60 and 100</p></td></tr><tr><td style="vertical-align:top"><p>1 week intravenous study in dogs</p><p>(1M, 1F/dose group)</p></td><td style="vertical-align:top"><p>10, 15 and 30 mg/kg bid</p></td></tr><tr><td style="vertical-align:top"><p>1 month intravenous study in rats</p><p>(3M, 3F/dose group)</p></td><td style="vertical-align:top"><p>2, 10 and 50</p></td></tr><tr><td style="vertical-align:top"><p>1 month oral study in rats</p><p>(12M, 12F/dose group)</p></td><td style="vertical-align:top"><p>30, 100 and 400 in males</p><p>100, 200 and 400 in females</p></td></tr><tr><td style="vertical-align:top"><p>1 month intravenous study in dogs</p><p>(3M, 3F/dose group)</p></td><td style="vertical-align:top"><p>2, 5 and 20 mg/kg bid</p></td></tr><tr><td style="vertical-align:top"><p>1 month oral study in dogs</p><p>(1M, 1F/dose group)</p></td><td style="vertical-align:top"><p>5, 100 and 200 as gelatin capsules</p><p><strong>&nbsp;</strong>60 for 1 week then 100 for 3 weeks</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Study</strong></p></td><td style="vertical-align:top"><p><strong>Alfuzosin</strong><strong> </strong><strong>doses</strong><strong> in mg/kg/day (Oral administration)</strong></p></td></tr><tr><td style="vertical-align:top"><p>1 month study in dogs</p><p>(2M, 2F/dose group)</p></td><td style="vertical-align:top"><p>50, 100 and 200 as gelatin capsules</p></td></tr><tr><td style="vertical-align:top"><p>1 month study in dogs</p><p>(3M, 3F/dose group)</p></td><td style="vertical-align:top"><p>20 mg/animal of 5 mg SR tablets</p></td></tr><tr><td style="vertical-align:top"><p>3 month toxicity in rats</p><p>(20M, 20F/dose group)</p></td><td style="vertical-align:top"><p>5, 30 and 200</p></td></tr><tr><td style="vertical-align:top"><p>3 month study in dogs</p><p>(3M, 3F/dose group)</p></td><td style="vertical-align:top"><p>5, 20 and 80</p></td></tr><tr><td style="vertical-align:top"><p>6 month toxicity in rats</p><p>(25M, 25F/dose group)</p></td><td style="vertical-align:top"><p>10, 50 and 250</p></td></tr><tr><td style="vertical-align:top"><p>1 year study in rats</p><p>(20M, 20F/dose group)</p></td><td style="vertical-align:top"><p>1, 5 and 25</p></td></tr><tr><td style="vertical-align:top"><p>1 year study in dogs</p><p>(7M, 7F/dose group)</p></td><td style="vertical-align:top"><p>5, 20 and 80</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In the 1 week intravenous studies in rats, 3 animals died on days 1, 3 and 5 as a result of severe cardiac depression. Survivors exhibited prostration, dyspnea, sialorrhea, peripheral vasodilation and palpebral ptosis. No lesions were observed at injection sites. When dogs were administered alfuzosin intravenously for one week, no deaths occurred and clinical symptoms consisted of peripheral vasodilation, nasal dryness, diarrhea, hypotonia, tremor, protrusion of the nictitating membrane and hyperdacryorrhea. Palpebral ptosis was observed at 15 and 30 mg/kg bid with vomiting and salivation occurring at 30 mg/kg bid. In a one month intravenous study in dogs, no deaths occurred and no lesions were evident at injection sites. However clinical symptoms such as peripheral vasodilation, palpebral ptosis, nasal dryness, tachypnea, tachycardia and some hypotonia, vomiting, and ptyalism were recorded.</p><p>In one month oral studies in rats, clinical signs began to appear at 100 mg/kg/day for males and 200 mg/kg/day for females and consisted mainly of sedation, hypersalivation, slight changes in haematology as well as increased triglycerides. When rats where treated by i.v. route with 2, 10 or 50 mg/kg/day alfuzosin three deaths occurred in the first week. Clinical symptoms included palpebral ptosis, hypotonia, ocular secretions, peripheral vasodilation, respiratory difficulties and vaginal dilation.</p><p>Beagle dogs treated with 200 mg/kg/day for 4 weeks demonstrated motor incoordination and loss of appetite accompanied by a reduction in water intake. A dose of 200 mg/kg/day also produced an increase in SGPT, proteinuria, haematuria and renal lesions. When dogs were treated with 60 mg/kg/day for one week followed by 100 mg/kg/day for 3 weeks, clinical symptoms were mild and consisted of vomiting and diarrhea, tremor, sedation, vasodilation, palpebral ptosis and abnormal gait. Similar symptoms were observed in dogs treated for 3 months with 80 mg/kg/day. When dogs were treated with the 5 mg SR formulation for one month (20 mg/animal/day) no clinical signs and no deaths were observed. Body weight and food consumption were normal. In addition, dogs treated with 2, 5 or 20 mg/kg bid by IV route demonstrated typical clinical symptoms but no deaths were observed.</p><p>In 3 month toxicity studies in rats, 200 mg/kg /day caused transient hypersalivation, mild anaemia, increased urine output and weight changes of adrenal glands and spleen in males. When dogs were treated with alfuzosin 5, 20 or 80 mg/kg/day for 3 months, no deaths occurred and clinical symptoms included soft feces, vomiting, tremor, peripheral vasodilation and hyper salivation at 20 and 80 mg/kg/day. In addition, abnormal quietness was observed at all doses.</p><p>Rats treated with alfuzosin for 6 months demonstrated marked accumulation of the compound in blood and histopathological changes in adrenal tissue at 50 mg/kg/day in males and 250 mg/kg/day in females as well as liver cell changes such as necrosis of cells around acinus and cytoplasmic eosinophilia. In a this 6 month toxicity study, rats of both sexes were divided into four groups and administered 10, 50 or 250 mg/kg/day alfuzosin or control. Twenty-two animals died out of which 4 cases were considered not related to treatment. The deaths were dose-related (2 males at 50 mg/kg/day, 7 males and 9 females at 250 mg/kg/day). Rats administered 250 mg/kg/day and 2 males at 50 mg/kg/day died within 30 minutes after oral gavage and exhibited respiratory difficulties, hypersalivation and peripheral vasodilation prior to death. The other animals died between 2 and 22 hours following administration of alfuzosin. Alfuzosin also caused ptosis and peripheral vasodilation from Week 1 and peripheral redness of the eyes and vaginal dilation from Week 2. Rats receiving 50 and 250 mg/kg/day showed a dose-related frequency of salivation (from Week 2) and urogenital wetness (from Week 7). Food consumption slightly increased in all animals with the exception of males receiving 250 mg/kg/day who lost all appetite from Week 9.</p><p>When rats were treated with alfuzosin 1, 5 or 20 mg/kg/day for one year clinical symptoms were ptosis at 5 and 25 mg/kg/day and scrotal reddening and vaginal dilation in all treatment groups. Increased weight gain was observed in females at 25 mg/kg/day after Month 1. Food consumption was increased in males at the two higher doses and females at 25 mg/kg/day. Water consumption was normal. Twelve animals died or were sacrificed, however 8 cases were not treatment related. Organ weight examination revealed increases in the pituitary gland in females, the kidney and thyroid in males and the liver and spleen in both sexes.</p><p>Oral administration of alfuzosin to dogs for 53 weeks is characterized by a fairly wide range of clinical symptoms such as photophobia, tremor, palbebral ptosis, nasal dryness and soft feces. However laboratory and physiological tests did not show any treatment related effects.</p><p>Macroscopic and microscopic examinations revealed impairment of the female reproductive cycle.</p><p>&nbsp;</p><p><strong><u>Carcinogenicity Studies</u></strong></p><p>Carcinogenicity studies were carried out in the mouse and rat. Alfuzosin was shown to have no carcinogenic effect. In a 98-week oral carcinogenicity study in mice, alfuzosin was administered at doses with vehicle control to groups of 51 males and 51 females in 2 sub-groups. Mortality was increased in males at 100 mg/kg/day (53% in controls, 78% in the 100 mg/kg/day group).</p><p>There were very slight increases in the relative weight of the liver in a few males who received 100 mg/kg/day of alfuzosin. No tumoral or other types of lesions were observed. At doses up to 100 mg/kg/day, alfuzosin had no carcinogenic potential in mice.</p><p>In a 104-weeks oral carcinogenicity study in rats, alfuzosin was administered at doses of 10, 30 and 100 mg/kg/day, with vehicle control, to groups of 50 males and 50 females in 2 sub-groups. Mortality was comparable in all doses. No oncogenic effect was noted.</p><p>&nbsp;</p><p><strong><u>Mutagenicity Studies</u></strong></p><p>Alfuzosin did not show any mutagenic potential in the AMES test, mouse lymphoma test, chromosomal aberrations test in Chinese hamster ovary cells, unscheduled DNA repair test and mouse micronucleus test.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Reproduction and Teratogenicity Studies</u></strong></p><p>Studies were carried out in the Sprague Dawley rat and the New Zealand rabbit. Alfuzosin was not embryotoxic, produced no teratogenic effects and did not affect fertility, parturition or lactation at dose levels many-fold greater than therapeutic levels in man.</p><p>A preliminary fertility study in Sprague Dawley rats established that the maximum dose to be used in the principal fertility study should be &lt; 200 mg/kg/day. The principal study utilized groups of 26 male and female animals who received alfuzosin by gavage at doses of 5, 25 and 125 mg/kg/day, with vehicle control. Males were treated from Day 71 prior to mating to the end of gestation of the female. Females were treated from Day 15 prior to mating to Day 21 post- coitum and half of the females to Day 25 post-partum. The vaginal cytological cycle was altered at doses of 25 and 125 mg/kg/day of alfuzosin, but alfuzosin had not effect on mating, ovulation or pre- and post-natal development. The &ldquo;No Adverse Effect Level&rdquo; for the F0 generation was 5 mg/kg/day. The viability of the offspring was reduced at a dose of 125 mg/kg/day but the reproductive behaviour of the F1 generation was not changed following treatment of the parents. Consequently, the &ldquo;No Adverse Effect Level&rdquo; for the F1 and F2 generations was considered to be 25 mg/kg/day.</p><p>In a peri- and post-natal study in the rat, alfuzosin was administered from Day 15 post-coitum to Day 21 post-partum at doses of 5, 25 and 125 mg/kg/day, with vehicle control, to groups of 20 females. Alfuzosin at these doses caused no abnormalities in parents or pups. The &ldquo;No Adverse Effect Level&rdquo; for the F0 generation was 5 mg/kg/day and for the F1 generation was 125 mg/kg/day.</p><p>Teratogenicity studies were carried out in the rat and rabbit. Alfuzosin produced no teratogenic effects.</p><p>Alfuzosin was administered by gavage to three groups of females rats at various dose levels, with vehicle control, from Day 6 to Day 15 of gestation. In a preliminary study, 15 animals received 100 or 200 mg/kg/day. In the main study, 20 animals received 10, 50 or 250 mg/kg/day. These studies showed no effect of alfuzosin on organogenesis up to a dose of 250 mg/kg/day. The &ldquo;No Adverse Effect Level&rdquo; for the F0 and F1 generations was 250 mg/kg/day.</p><p>Alfuzosin was administered by gavage to two groups of females rabbits at various dose levels, with vehicle control from Day 6 to Day 18 of gestation. In a preliminary study, 4 animals received 50, 100 or 250 mg/kg/day. In the main study, 14 animals received 10, 30 or 100 mg/kg/day. These studies showed no effect of alfuzosin on organogenesis up to a dose of 100 mg/kg/day. The &ldquo;No Adverse Effect Level&rdquo; for the F0 generation was 10 mg/kg/day and for the F1 generation was 30 mg/kg/day.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Cytotoxicity Studies</u></strong></p><p>Alfuzosin was administered in vitro to cultures of hepatocytes from males Sprague Dawley rats and male Beagle dogs at concentration from 1.25 to 100 &mu;M. Findings were similar in both species: Alfuzosin induced gradual membrane and metabolic damage. However the IC50&nbsp;was &gt;100 &mu;M. Alfuzosin was otherwise well tolerated by hepatocytes at these concentrations.</p><p>&nbsp;</p><p><strong><u>Immunotoxicity Studies</u></strong></p><p>Sensitization studies carried out in male and female Dunkin Hartley albino guinea pigs showed that alfuzosin had a mild sensitizing capacity at oral doses of 6-10 mg/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In addition to the active ingredient, alfuzosin hydrochloride, each tablet also contains the non- medicinal ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl methylcellulose, magnesium stearate, polyvinyl acetate phthalate, and yellow ferric oxide.</p><p>For a complete quantitative listing, see Section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg; C. Keep in a safe place out of the reach of children. No special precautions applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:681px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:58px"><p>Strength</p></td><td style="vertical-align:top; width:37px"><p>Unit Count or Fill Size</p></td><td style="vertical-align:top; width:64px"><p>Container Size(s)</p></td><td style="vertical-align:top; width:490px"><p>Description</p></td></tr></tbody></table><table align="left" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:66px" rowspan="3"><p>10 mg</p></td><td style="vertical-align:top; width:62px" rowspan="3"><p>30&#39;s</p><p>&nbsp;</p></td><td style="vertical-align:top; width:74px" rowspan="3"><p>Blisters</p></td><td style="vertical-align:top; width:510px"><p>Film &nbsp;PVC/PVdC &nbsp;clear&nbsp; 10MIL 250/601&nbsp; &nbsp;130mm:</p></td></tr><tr><td style="vertical-align:top; width:510px"><p>Clear, transparent plastic &nbsp;film, smooth on both sides. Approximately 130 mm wide.</p><p>Foil Silver Plain 130mm1&nbsp;&nbsp;25b m:</p></td></tr><tr><td style="vertical-align:top; width:510px"><p>Dull silver on &nbsp;one side, shiny &nbsp;silver on other. Rolled material approximately 130 mm wide.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Secondary packaging: Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 150 Signet Drive Toronto, Ontario Canada, M9L 1T9
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>